Excellent post Pete and I agree with all of your p

Excellent post Pete and I agree with all of your points. Today’s PR validated what most long term investors fully expected as Brilacidin once again has been proven to be safe even with extensive and consecutive dosing. This is a huge milestone validating the safety profile. One of the key reasons for Brilacidin’s outstanding Selectivity Index (SI) was the safety advantage over repurposed antivirals. The 5 day dosing will be easier to directly compare Brilacidin vs both SOC’s of Remdesivir and Favipiravir. If Brilacidin proves its efficacy in this human trial vs CV19 similar to how it performed in extensive RBL testing, Brilacidin will become the new standard of care for moderate and severe COVID patients.

We could soon hear news in regards to Brilacidin as a Pan-Coronavirus treatment, as an all-purpose antiviral as well as progress on instances for B-IBD UC and B-OM. There are multiple opportunities for Brilacidin to get fully approved with multiple markets to pursue.

The MM’s are struggling to show volume as no one with half a brain would be selling at this point of IPIX’s history. You cannot have real volume without both buyers and sellers. When news hits that Brilacidin is a proven CV19 killer we will see a run of 10M+ volume days and the criminals will start to lose their control over IPIX SP. The next few months will be exciting times for long term IPIX investors.